

in advanced CKD: role in endotoxaemia and inflammation. *BMC Nephrol.* 2020;21(1):118. doi: 10.1186/s12882-020-01779-9.

54. Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating *Aspergillus* markers in a patient with chronic granulomatous disease and invasive aspergillosis. *J Clin Microbiol.* 2000;38(10):3900-1. doi: 10.1128/JCM.38.10.3900-3901.2000.

55. Leeflang MMG, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJP, Hooft L, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. *Cochrane Database Syst Rev.* 2015;2017(12):CD007394. doi: 10.1002/14651858.CD007394.pub2.

56. Bassetti M, Azoulay E, Kullberg B-J, Ruhnke M, Shoham S, Vazquez J, et al. EORTC/MSGRC definitions of invasive fungal diseases: Summary of activities of the intensive care unit working group. *Clin Infect Dis.* 2021;72(Suppl 2):S121-7. doi: 10.1093/cid/ciaa1751.

57. Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. *Clin Infect Dis.* 2014;59(12):1696-702. doi: 10.1093/cid/ciu673.

58. Lai G, Zeng C, Mo J, Song W-D, Xu P. Diagnostic value of galactomannan in bronchoalveolar lavage fluid for chronic respiratory disease with pulmonary aspergillosis. *J Clin Microbiol.* 2020;58(3). doi: 10.1128/jcm.01308-19.

59. de Heer K, Gerritsen MG, Visser CE, Leeflang MM. Galactomannan detection in bronchoalveolar lavage fluid for invasive aspergillosis in immunocompromised patients. *Cochrane Database Syst Rev.* 2019;5(4):CD012399. doi: 10.1002/14651858.CD012399.pub2.

60. Nuh A, Ramadan N, Shah A, Armstrong-James D. Sputum galactomannan has utility in the diagnosis of chronic pulmonary aspergillosis. *J Fungi (Basel).* 2022;8(2):188. doi: 10.3390/jof8020188.

61. Chun JY, Jeong S-J, Kim S, Choi S, Lee JH, Chung HS, et al. Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samples. *J Infect.* 2024;88(6):106159. doi: 10.1016/j.jinf.2024.106159.

62. Zandijk E, Mewis A, Magerman K, Cartuyvels R. False-positive results by the platelia *Aspergillus* galactomannan antigen test for patients treated with amoxicillin-clavulanate. *Clin Vaccine Immunol.* 2008;15(7):1132-3. doi: 10.1128/CVI.00022-08.

63. Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of platelia *Aspergillus* galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. *Antimicrob Agents Chemother.* 2004;48(6):1989-92. doi: 10.1128/AAC.48.6.1989-1992.2004.

64. Boonsarnsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. False-positive serum and bronchoalveolar lavage *Aspergillus* galactomannan assays caused by different

antibiotics. *Scand J Infect Dis.* 2010;42(6-7):461-8. doi: 10.3109/00365541003602064-

65. Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, et al. Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible for false-positive results of the galactomannan assay. *J Antimicrob Chemother.* 2012;67(7):1746-8. doi: 10.1093/jac/dks111.

66. Penack O, Schwartz S, Thiel E, Wolfgang Blau I. Lack of evidence that false-positive *Aspergillus* galactomannan antigen test results are due to treatment with piperacillin-tazobactam. *Clin Infect Dis.* 2004;39(9):1401-2; author reply 1402-3. doi: 10.1086/425131.

67. Shin DW, Cho J, Choi KS, Lee J, Choi Y, Choi SJ, et al. False-positive results of galactomannan assays in patients administered glucose-containing solutions. *Sci Rep.* 2024;14(1):2552. doi: 10.1038/s41598-024-53116-x.

68. Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for *Aspergillus* galactomannan in bronchoalveolar lavage fluid. *J Clin Microbiol.* 2007;45(2):676-7. doi: 10.1128/JCM.01940-06.

69. Van Der Veer J, Lewis RJ, Emtiazoo AM, Allen SD, Wheat LJ, Hage CA. Cross-reactivity in the PlateliaTM *Aspergillus* enzyme immunoassay caused by blastomycosis. *Med Mycol.* 2012;50(4):396-8. doi: 10.3109/13693786.2011.608172.

70. Wheat LJ, Hackett E, Durkin M, Connolly P, Petraitiene R, Walsh TJ, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia *Aspergillus* enzyme immunoassay. *Clin Vaccine Immunol.* 2007;14(5):638-40. doi: 10.1128/CVI.00479-06.

71. Dalle F, Charles PE, Blanc K, Caillot D, Chavanet P, Dromer F, et al. *Cryptococcus neoformans* Galactoxylomannan contains an epitope(s) that is cross-reactive with *Aspergillus* Galactomannan. *J Clin Microbiol.* 2005;43(6):2929-31. doi: 10.1128/JCM.43.6.2929-2931.2005.

72. Aigner M, Wanner M, Kreidl P, Lass-Flörl C, Lackner M. *Candida* in the respiratory tract potentially triggers galactomannan positivity in nonhematological patients. *Antimicrob Agents Chemother.* 2019;63(6). doi: 10.1128/AAC.00138-19.

73. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. False-positive *Aspergillus* galactomannan antigenaemia after haematopoietic stem cell transplantation. *J Antimicrob Chemother.* 2008;61(2):411-6. doi: 10.1093/jac/dkm463.

74. Mennink-Kersten MASH, Ruegebrink D, Klont RR, Warris A, Gavini F, Op den Camp HJM, et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia *Aspergillus* enzyme-linked immunosorbent assay reactivity. *J Clin Microbiol.* 2005;43(8):3925-31. doi: 10.1128/JCM.43.8.3925-3931.2005.

75. Ansorg R, van den Boom R, Rath PM. Detection of *Aspergillus* galactomannan antigen in foods and antibiotics. *Mycoses.* 1997;40(9-10):353-7. doi: 10.1111/j.1439-0507.1997.tb00249.x.